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Abstract
In this review, we will describe several recent HIV-1 studies in which a drug-dependent virus variant
was selected. A common evolutionary route to the drug-dependence phenotype is proposed. First,
the selection of a drug-resistance mutation that also affects the function of the targeted viral
protein. Second, a compensatory mutation that repairs the protein function, but in the presence of
the drug, which becomes an intrinsic part of the mechanism. The clinical relevance of drug-
dependent HIV-1 variants is also discussed.
Introduction to the HIV-1 drug-dependence 
phenomenon
We previously described the emergence of a drug-depend-
ent HIV-1 variant in a patient on T20 (enfuvirtide) therapy
[1]. This variant first acquired a resistance mutation in the
T20-binding site of the envelope (Env) protein that pro-
vided resistance to the inhibitor, but at a fitness cost. The
virus then evolved further to repair this fitness defect by
introducing a second-site compensatory mutation in the
Env protein. This evolution event took place in the pres-
ence of the inhibitor, which became critically involved in
the mechanism of Env-mediated membrane fusion. This
resulted in a virus variant with improved fitness that was
both resistant and critically dependent on the inhibitor
for its replication.
There have been several in vitro reports on the selection of
partially and fully drug-dependent HIV-1 variants to a
number of antiviral compounds that target different steps
in the virus life cycle. We will argue that, in many cases,
the evolution of the drug-dependence phenomenon
occurs via a similar path: the selection of initial drug-
resistance mutations that reduce the fitness of the virus,
and subsequently the introduction of second-site com-
pensatory mutations that evolve in the presence of inhib-
itor to improve the fitness of the virus. This scenario may
result in a better replicating virus variant that mechanisti-
cally uses the inhibitor and such a variant will show
severely reduced fitness when the inhibitor is removed
from the environment.
The evolution of drug-dependence may depend on the
mechanistic nature of the inhibitor. For example, inhibi-
tors that mimic a certain sequence or domain of the virus
such as the fusion inhibitor T20 may be more prone to
select for drug-dependent viruses as the mimicking pep-
tide is able to become involved in the mechanistic process
of Env-mediated membrane fusion. As discussed in more
detail below, protease resistant HIV-1 variants could also
adapt and optimize protease activity in the presence of a
protease inhibitor [2], but no such phenomenon has been
reported thusfar for reverse transcriptase inhibitors. We
will review all studies that report drug-enhanced or drug-
dependent HIV-1 variants. There is a growing body of evi-
dence to suggest that drug-dependence is a more common
phenomenon. In many cases, drug-dependence will be
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missed because the virus does not replicate without the
drug, which is usually an indication for the researcher to
stop any further experimentation. Furthermore, a drug-
dependence phenotype will easily be missed in the diag-
nostic resistance screening assays used today such as the
MTT assay.
HIV-1 entry and the T20-dependence phenotype
HIV-1 enters the human cell in 3 main steps: 1) attach-
ment of the viral surface Env gp120 protein to the CD4
receptor on the target cells; 2) subsequent interaction of
the Env-CD4 complex with a coreceptor, and 3) virus-cell
membrane fusion mediated by the Env transmembrane
gp41 protein. Changes within gp41 involve two leucine
zipper-like motifs; heptad repeat 1 (HR1) and heptad
repeat 2 (HR2) assembling into a highly stable six-helix
bundle structure, which juxtaposes the viral and cellular
membranes for the fusion event [3-5]. Peptide fusion
inhibitors such as T20 can bind to one of the HR motifs
and block this conformational switch, and thus inhibit
viral entry [6-9].
It is generally agreed upon that resistance to T20 is gov-
erned by changes in the HR1 region of gp41, specifically
in a stretch of amino acids in and adjacent to the GIV
motif (amino acids 36–45 of gp41) (Fig. 1A) [10]. There
is accumulating evidence that other Env domains outside
the HR1 domain also play a role. This role is either direct,
e.g. in the formation of a fusogenic structure that is tar-
geted by T20 and hence can modulate virus sensitivity to
T20, or indirect by restoring Env function. One of these
regions is the HR2 domain of gp41 that plays a crucial role
in the formation of the 6-helix bundle as it folds in an
anti-parallel fashion onto the pre-formed trimer of HR1
helixes.
In our report on the in vivo emergence of a T20-depend-
ent virus [1], we described for the first time an HR2 amino
acid change that was involved in T20-resistance. Briefly,
we performed a genetic analysis of the entire HIV-1 gp41
ectodomain in the viral population from a patient that
failed on T20 therapy. Sequence analysis revealed the
acquisition of the known T20-resistance mutation GIA
(GIV to GIA; mutated amino acid underlined) in HR1, but
we also documented a subsequent change in a three
amino acid SNY sequence of the HR2 domain (SNY to
SKY). We demonstrated that the HR1-HR2 double mutant
(GIA-SKY), which dominated the viral population after 32
weeks of therapy, was not only highly resistant to T20, but
also critically dependent on the T20 peptide for its repli-
cation.
We proposed a mechanistic model that supports this
novel feature of drug-dependent viral entry (Fig. 1B) [1].
Briefly, resistance to T20 is caused by the GIA mutation in
HR1, which weakens the interaction with both T20 (resist-
ance) and HR2 (gp41 6-helix bundle formation). The
reduced HR1-HR2 affinity negatively impacts Env-medi-
ated fusion and HIV-1 fitness [1,11]. The T20-dependence
phenotype is caused by the SKY mutation in HR2, which
stabilizes the HR1-HR2 interaction [1]. However, the SKY
mutation creates a hyper-fusogenic Env-gp41 molecule
that prematurely undergoes the conformational switch,
which effectively kills virus infectivity. T20 is able to pre-
vent this premature switch by preserving an earlier pre-
fusion conformation, enabling gp41 to undergo the nec-
essary conformational switch at the correct moment in the
fusion process. The T20-control should be transient, as the
peptide should leave the complex to allow the subsequent
HR1-HR2 interaction.
We subsequently provided further evidence for this mech-
anistic model. First, according to this mechanistic model
of T20-dependence, any compound that transiently inter-
feres with the HR1-HR2 interaction should be able to sup-
port the replication of the T20-dependent virus. This
critical test was performed with HR1- and HR2-targeting
peptides and antibodies, and the results confirm the pro-
posed mechanism (submitted for publication). The only
exception was the T1249 fusion inhibitor, which acts as a
dominant inhibitor because it does not leave the Env
complex in time. This result indicates that the drug-
dependence phenomenon can also be used in the preclin-
ical testing of improved entry inhibitors, which should
preferentially not stimulate the T20-dependent HIV-1 var-
iant. Second, we used virus evolution to obtain insight
into the T20-dependence mechanism [12]. Specifically,
we allowed the T20-dependent virus to evolve in the
absence of T20 to regain T20-independence. Escape vari-
ants with improved replication capacity appeared in 5
evolution cultures. Strikingly, 3 of these cultures selected
the same amino acid change in the CD4 binding site of
Env (glycine at position 431 substituted for arginine:
G431R). This mutation was sufficient to abolish the T20-
dependence phenotype by restoring viral replication in
the absence of T20. Further experimentation indicated
that the premature conformational switch is delayed by
the second-site mutation in Env that affects the interac-
tion with the CD4 receptor.
How general is the T20-dependence phenotype: 
a common HR1-HR2 theme
Numerous clinical studies have reported T20-resistance
mutations [1,10,11,13-20]. One clinical trial that enrolled
17 patients was used to track the evolution of sequence
changes in HR1 and HR2 that are associated with T20-
resistance [14]. Mutations in HR1 (amino acids 36–45)
were noted in all patients. Isolates from 6 of 17 patients
also developed the subsequent S138A change in HR2. It
was proposed that the S138A mutation represents a com-Retrovirology 2007, 4:78 http://www.retrovirology.com/content/4/1/78
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pensatory mutation that increases T20-resistance, particu-
larly when it co-exists with mutations at position 43 in
HR1. Interestingly, careful analysis of the published
results revealed a SIM-DKY variant in one of the patients
after 24 weeks of therapy. This mutant resembles the T20-
dependent GIA-SKY variant that we described [1]. How-
ever, little additional information is available, as not all
mutations were tested in a molecular HIV-1 clone and
analyzed for possible drug-resistance and drug-depend-
ence. Studies that reported combined HR1/HR2 changes
are summarized in Table 1.
(A) Schematic of gp160, the gp120 and gp41 subunits and a close-up of the gp41 ectodomain Figure 1
(A) Schematic of gp160, the gp120 and gp41 subunits and a close-up of the gp41 ectodomain. Indicated are the positions and 
amino acid residues of peptide based fusion inhibitor T20. The GIV sequence in HR1 (position 36–38) of gp41 is underlined. 
(B) Proposed model for T20-dependent viral entry. Each box depicts one of three scenarios: T20-sensitive (GIV-SNY), T20-
resistant (GIA-SNY) and T20-dependent (GIA-SKY). A simplified gp41 ectodomain comprised of only one subunit of HR1 (light 
grey cylinder) and HR2 (dark grey cylinder) joined by a loop region (black line) is used to depict a pre-fusion and post-fusion 
state of the peptide. The thickness of the arrows represents the speed of the conformational switch between pre- and post-
fusion conformations. A white star represents the GIA mutation in HR1 and a black star represents the SKY mutation in HR2. 
Explanations for each reaction are provided on the right hand side.
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Another clinical trial study analyzed amino acid changes
in the gp41 region of Env over a 40–72 week period in 4
patients that received T20 on top of an optimized antiviral
regimen [13]. Three of the four patients initially devel-
oped T20-resistance mutations in the HR1 region and
subsequently developed HR2 mutations. HR1 mutations
occurred in the amino acid region 36–45 (G36D/E, N42T,
N43D and L45M), whereas S138A was again the main
mutation observed in HR2. Although they did not per-
form molecular recloning experiments, it can be con-
cluded that compensatory changes in HR2 develop
frequently within the course of T20 therapy.
Two very recent 2007 studies reported interesting com-
pensatory changes in HR2 within the virus population of
patients on T20 therapy [17,21]. The first study describes
five treatment-experienced patients that were analyzed for
Env sequences prior to T20 therapy and at the point of
virologic failure [17]. The same double mutant that we
reported [1], GIA-SKY, was isolated from one patient and
confirmed to be highly resistant to T20. However, drug-
dependence was not tested. In fact, all patients developed
both HR1 and HR2 mutations, including the S138A
change in HR2, which was seen in combination with the
N43D mutation in HR1 in one patient.
In the second study, Env sequences were analyzed during
the course of T20-therapy in 5 patients [21]. The N43D
mutation in HR1 provided resistance to T20, but at a large
fitness cost (92% decreased infectivity was measured). An
interesting compensatory mutation in HR2 (E137K)
restored the infectivity defect and further increased resist-
ance to T20.
Thus, mutations in HR1 at residue 43 trigger a response in
HR2 at residue 137 (E137K) or 138 (S138A). Interest-
ingly, these HR1 and HR2 amino acid residues are juxta-
posed in the post-fusion 6-helix bundle structure [14].
The introduction of N43D in HR1 introduces a negatively
charged aspartic acid (D), which may be unfavorable in
the formation of the 6-helix bundle as it approaches the
negatively charged glutamic acid (E) at position 137. The
compensatory HR2 mutation introduces a positively
charged lysine (K) or a neutral charged alanine (A), which
will avoid the repulsion and thus restore virus infectivity.
T20-like drugs: a common HR1-HR2 theme
A novel gene therapy approach used a membrane-
anchored gp41-derived peptide (M87) that includes the
T20 sequence, which can protect cells from HIV-1 infec-
tion [22]. In an effort to characterize the mechanism of
action of the membrane-anchored peptide in comparison
to the soluble peptide T20, resistant HIV-1 variants were
selected by serial virus passage using cells stably express-
ing the M87 peptide [23]. Sequence analysis of the resist-
ant variants revealed the HR1 change I48V in
combination with the HR2 change N126K, which is the
same as the SKY mutation in the T20-dependent variant
[1]. This double mutant was confirmed to be resistant to
T20 but had a severe reduction in viral fitness in the
absence of the T20 peptide.
Nameki et al [24] generated variants resistant to the C34
fusion inhibitor that has a similar mode of action as T20
[7,25]. A resistant variant with the I37K mutation in the
GIV motif of HR1 and again the N126K mutation in the
SNY motif in HR2 was reported. Binding assays revealed
that the I37K mutation in HR1 impaired the binding of
the C34 peptide, whereas the N126K mutation enhanced
HR2 binding to the mutated HR1.
It is generally accepted that HR1 mutations cause resist-
ance to T20/C34. The combined results indicate that HR2
mutations also play a major role in T20/C34-resistance
development. HR2 changes may directly impact on the
resistance phenotype, but are more likely to influence
viral fitness because uncompensated HR1 mutations slow
the fusion kinetics and reduce viral fitness [1,11]. Further
studies should investigate the compensatory role of HR2
mutations on Env fusion kinetics and possibly drug-
dependence.
Table 1: Combined HR1-HR2 mutations in the Env protein
Inhibitor gp41 mutations Report
T20 HR1 HR2
T20 V38A (GIA) N126K (SKY) Baldwin et al, 2004
Ray et al, 2007
M87 (membrane anchored T20) I48V N126K Hildinger et al, 2001
C34 I37K N126K Nameki et al, 2005
Retrocyclin RC-101 Q66R N126K Cole et al, 2006
T20 N43D S138A Xu et al, 2005
Perez-Alvarez et al, 2006
Ray et al, 2007
T20 N43D E137K Tolstrup et al, 2007Retrovirology 2007, 4:78 http://www.retrovirology.com/content/4/1/78
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Other drug-dependencies in the Env protein
A 2006 report by Cole et al described the in vitro selection
of resistant virus variants to retrocyclin RC-101 [26]. This
drug is a cationic θ-defensin that inhibits HIV-1 entry by
blocking 6-helix bundle formation in a similar manner to
fusion inhibitors such as T20 and T1249 [27]. The resist-
ant variants that emerged had mutations in HR1 and HR2
of gp41 as well as the CD4 binding domain of gp120 (C4
domain). It was noted that the HR1/HR2 double mutant,
but also the HR1/HR2/C4 triple mutant, were not able to
adequately infect cells in the absence of RC-101. Addition
of RC-101 restored infectivity in a dose-dependent man-
ner. Interestingly, the HR2 mutation is identical to the
SKY (N126K) mutation that we reported in the T20-
dependent virus [1].
Recently, a drug-enhancement phenotype was reported
for an inhibitor-bound form of the CCR5 co-receptor
[28]. HIV-1 infection can be inhibited by small molecules
that target the CCR5 coreceptor and one of the most
promising drugs is SCH-D (Vicriviroc) [29]. It was dem-
onstrated that the fully SCH-D resistant viruses with
mutations in the Env gene, enter target cells by recogni-
tion of the SCH-D bound form of CCR5. SCH-D does not
inhibit these resistant viruses, and even enhances their
infectivity modestly.
Drug-enhancement of the HIV-1 protease
In 2003, Menzo et al described a partially drug-dependent
phenomenon (drug-enhancement) when they reported
that HIV-1 variants that are resistant to a protease inhibi-
tor have enhanced fitness in the presence of the drug [2].
The drug-enhancement effect was associated with a large
number of protease mutations and no single amino acid
substitution that is responsible for this drug-enhancement
could be identified. However, this report demonstrated
that the virus could adapt and optimize protease activity
in the presence of the inhibitor, which is of clinical signif-
icance as protease inhibitors are used extensively to treat
HIV infected patients.
Drug-dependence of the HIV-1 Gag protein
An in vitro study by Aberham et al in 1996 selected HIV-1
variants that are resistant to a non-immunosuppressive
analog of cyclosporin A (CsA) [30]. The phenotype of all
variants was not just drug-resistance, but full drug-
dependence. The mutants selected in this study provided
the first evidence that mutations in the Gag protein can
confer resistance to CsA, and that these resistant variants
were also critically dependent on CsA for their replication.
Furthermore, the drug-dependent phenotype is very strin-
gent, and only revertant viruses with the parental pheno-
type grew out in the absence of CsA. Subsequent reports
proposed a mechanism of HIV-1 resistance to CsA
[31,32]. Briefly, HIV-1 requires the incorporation of the
peptidyl-prolyl isomerase cyclophilin A (CypA) into
maturing virus particles via contact with the proline-rich
domain of Capsid (CA) in the Gag polyprotein p55. Early
findings on the involvement of CypA suggested that incor-
poration is necessary for the production of infectious virus
particles [33,34]. More recent reports suggest that CypA
protects HIV-1 CA from a restriction factor in human cells
[35]. The mechanism will likely await identification of
this putative restriction factor [36].
CsA binds to CypA and inhibits its incorporation into the
virion particle. Resistance to CsA occurs when HIV-1 alters
the proline-rich domain in CA to effectively become
CypA-independent. Although the exact mechanism of
CsA-dependence is not known, numerous models have
been proposed [30-32,36]. Recently, a second-site com-
pensatory mutation in a distal CA domain was selected
that rescues the virus to a CsA-independent phenotype
[36]. This study parallels our work on the evolution of a
T20-independent variant [12].
In a recent 2006 study, Adamson et al reported a partial
drug-dependence phenotype for HIV-1 variants that
became resistant to the PA-457 (beviramat) inhibitor
[37]. This drug blocks a late step in the Gag processing
pathway, specifically the cleavage of SP1 from the C termi-
nus of CA. Similar to our report on T20-dependence, they
show that drug-resistant variants with a single resistance
mutation had diminished replication capacity and sec-
ond-site compensatory mutations were able to rescue
virus replication. Thus, the first resistance mutation sets
the stage for the second compensatory change that inte-
grates the drug in the mechanistic process.
Clinical implications of drug-dependent viruses
The evolution of drug-dependent HIV-1 variants has an
obvious clinical relevance. The appearance of such vari-
ants during antiviral therapy may be an indication to
modify the drug regimen. The switch to an alternative and
effective drug regimen will obviously solve the problem,
but we will discuss some other scenario's that specifically
relate to the presence of a drug-dependent virus. Another
problem is that the drug-dependence phenotype is easily
overlooked in diagnostic drug-resistance tests. Improved
screening assays would be of great advantage to patients as
physicians could better define the therapy regimens. It is
therefore important that current drug-resistance screening
assays are modified to be able to detect the appearance of
drug-dependent variants.
Should the treating clinician change the drug regimen
when a drug-dependent HIV-1 variant is selected? One
could consider stopping with the particular drug to which
the virus has become dependent. However, the impact on
the viral load will only be transient as archived drug-resist-Retrovirology 2007, 4:78 http://www.retrovirology.com/content/4/1/78
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ant and wild-type viruses will reappear quickly. Because
the wild-type virus is likely to have a higher fitness (with-
out drug) than the drug-dependent virus (with drug) it
may in fact be better to continue treatment. An alternative
approach would be to provide only sub-optimal amounts
of the drug in question, which should lead to down-regu-
lation of the viral load, yet prevent the reappearance of the
wild-type virus. However, drug-resistant variants are likely
to be favored in this context. Perhaps an alternating on/off
treatment scenario provides a good treatment alternative.
With drug, the drug-dependent virus will rapidly domi-
nate the quasispecies. Without drug, the wild-type (and
resistant) viruses will reappear. It is unclear if this on/off
regimen is beneficial for the patient. Similar drug holidays
are generally not advised, but the situation will be differ-
ent with the presence of drug-dependent viruses.
An interesting difference between drug-resistant and drug-
dependent viruses is at the level of the human population
and virus transmission. Drug-resistant viruses are known
to spread within the current epidemic [38], but this would
seem impossible for T20-dependent viruses because the
antiviral inducer drug is not available in the newly
infected individual. The actual situation will differ for dif-
ferent drug-dependencies. Entry and RT inhibitor depend-
ence will prevent the establishment of the integrated DNA
provirus in the recipient. Drug-dependence that acts at
later steps (e.g. Protease drugs) will also block virus repli-
cation, but only after an initial DNA provirus integration.
In general, drug-dependent viruses will not be able to
spread in the population, which could be another reason
to try to maintain such variants in patients with a high risk
profile of infecting others.
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